| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 19.778 | 26.410 | 17.987 | 29.321 | 57.582 | 52.133 | 35.043 | 4.825 |
| Total Income - EUR | - | - | 32.027 | 41.108 | 49.356 | 72.565 | 86.656 | 90.671 | 70.627 | 32.048 |
| Total Expenses - EUR | - | - | 33.071 | 40.061 | 65.875 | 52.828 | 57.692 | 51.442 | 71.754 | 46.729 |
| Gross Profit/Loss - EUR | - | - | -1.044 | 1.047 | -16.519 | 19.737 | 28.965 | 39.229 | -1.127 | -14.682 |
| Net Profit/Loss - EUR | - | - | -1.643 | 246 | -17.059 | 18.835 | 27.242 | 37.900 | -1.395 | -14.682 |
| Employees | - | - | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Glaxo Mialex Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 1.337 | 113.993 | 88.954 | 64.092 | 40.071 | 23.490 | 15.762 | 9.617 |
| Current Assets | - | - | 9.548 | 18.262 | 15.374 | 13.191 | 31.562 | 69.884 | 41.820 | 39.170 |
| Inventories | - | - | 6.123 | 3.232 | 6.539 | 3.946 | 11.417 | 22.478 | 6.480 | 4.303 |
| Receivables | - | - | 3.293 | 4.750 | 8.758 | 6.153 | 4.699 | 8.169 | 19.232 | 23.254 |
| Cash | - | - | 132 | 10.281 | 77 | 3.092 | 15.447 | 39.237 | 16.108 | 11.613 |
| Shareholders Funds | - | - | -1.599 | -1.324 | -18.357 | 825 | 28.049 | 66.036 | 41.192 | 26.280 |
| Social Capital | - | - | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | 12.484 | 26.488 | 38.581 | 14.463 | 3.025 | 6.777 | 15.790 | 22.507 |
| Income in Advance | - | - | 0 | 107.091 | 84.105 | 61.994 | 40.559 | 20.561 | 600 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "111 - 111" | |||||||||
| CAEN Financial Year |
111
|
|||||||||
Comments - Glaxo Mialex Srl